Discovery of Counterfeit Malaria Drugs
The National Agency for Food and Drugs Administration and Control (NAFDAC) has issued a public alert regarding the circulation of counterfeit Paludex Artemether/Lumefantrine tablets and suspensions in Nigeria. Laboratory analyses revealed that these fake drugs contained zero percent active pharmaceutical ingredients (APIs), posing significant risks to public health. The counterfeit products, reportedly manufactured by Impact Pharmaceutical Ltd and marketed by MD Life Sciences Ltd, are falsely labeled and unregistered in NAFDAC’s database.
Lab Analysis Reveals Health Threat
NAFDAC conducted tests on the counterfeit Paludex drugs at a WHO-certified laboratory in Germany, confirming the absence of APIs necessary for effective malaria treatment. The agency stressed that such fake medicines can lead to treatment failure and increased disease resistance, particularly among vulnerable groups like children. The findings highlight the importance of verifying the authenticity of medications to safeguard public health.
Surveillance and Enforcement Measures
NAFDAC has directed its zonal directors and state coordinators to intensify surveillance and remove these counterfeit products from the market. The agency called on distributors, healthcare providers, and consumers to remain vigilant, ensuring that only authorized suppliers are trusted for medical purchases. It also warned that individuals found distributing the fake drugs would face legal consequences.
Guidance for Healthcare Professionals and Consumers
The agency urged healthcare providers and the public to exercise caution when purchasing malaria medications. NAFDAC advised that all medicines be obtained from licensed suppliers and thoroughly inspected for authenticity. Any suspicious products should be reported immediately to the nearest NAFDAC office for investigation and proper action.
Potential Risks to Malaria Treatment
Genuine Artemether/Lumefantrine combinations are critical in treating malaria, especially in regions with high infection rates. NAFDAC warned that substandard or counterfeit drugs compromise treatment outcomes, potentially leading to severe health complications and increased mortality rates. Poor-quality pediatric formulations are of particular concern due to their impact on vulnerable patients.
NAFDAC’s Call to Action
NAFDAC has called on the public to discontinue the use of the counterfeit Paludex products and report any stock to the agency. The statement also encouraged those who may have consumed the fake drugs to seek immediate medical advice. By working together, healthcare professionals, consumers, and regulatory bodies can mitigate the risks posed by counterfeit medicines and protect public health.
Follow us on Socials: